全文获取类型
收费全文 | 5371篇 |
免费 | 239篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 111篇 |
妇产科学 | 65篇 |
基础医学 | 457篇 |
口腔科学 | 76篇 |
临床医学 | 404篇 |
内科学 | 1634篇 |
皮肤病学 | 84篇 |
神经病学 | 334篇 |
特种医学 | 264篇 |
外科学 | 1034篇 |
综合类 | 17篇 |
预防医学 | 97篇 |
眼科学 | 56篇 |
药学 | 289篇 |
中国医学 | 17篇 |
肿瘤学 | 683篇 |
出版年
2023年 | 27篇 |
2022年 | 31篇 |
2021年 | 119篇 |
2020年 | 71篇 |
2019年 | 92篇 |
2018年 | 136篇 |
2017年 | 107篇 |
2016年 | 112篇 |
2015年 | 139篇 |
2014年 | 176篇 |
2013年 | 213篇 |
2012年 | 385篇 |
2011年 | 366篇 |
2010年 | 238篇 |
2009年 | 155篇 |
2008年 | 301篇 |
2007年 | 371篇 |
2006年 | 331篇 |
2005年 | 373篇 |
2004年 | 391篇 |
2003年 | 398篇 |
2002年 | 347篇 |
2001年 | 53篇 |
2000年 | 49篇 |
1999年 | 56篇 |
1998年 | 75篇 |
1997年 | 78篇 |
1996年 | 50篇 |
1995年 | 48篇 |
1994年 | 49篇 |
1993年 | 44篇 |
1992年 | 30篇 |
1991年 | 30篇 |
1990年 | 29篇 |
1989年 | 25篇 |
1988年 | 22篇 |
1987年 | 23篇 |
1986年 | 12篇 |
1985年 | 13篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1982年 | 9篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 6篇 |
1975年 | 5篇 |
1972年 | 4篇 |
1970年 | 3篇 |
排序方式: 共有5653条查询结果,搜索用时 171 毫秒
1.
Masaki Shiota Eiji Kashiwagi Tomohiko Murakami Ario Takeuchi Kenjiro Imada Junichi Inokuchi Katsunori Tatsugami Masatoshi Eto 《Urologic oncology》2019,37(3):180.e19-180.e24
Purpose
Currently, several therapeutic options for castration-resistant prostate cancer (CRPC) are available, for which predictive biomarkers have not been established. Therefore, we aimed to reveal the association between pretreatment serum testosterone level and antitumor outcomes when treated with androgen receptor axis-targeting agents and taxane chemotherapies for CRPC.Patients and methods
The present study included Japanese patients with metastatic prostate cancer whose serum testosterone levels during androgen-deprivation therapy were available. The antitumor outcomes when treated with enzalutamide, abiraterone, docetaxel, and cabazitaxel with clinicopathological parameters including serum testosterone levels during androgen-deprivation therapy, as well as prognoses including progression-free survival and overall survival, were examined.Results
Progression-free survival among men with higher serum testosterone level was superior to that among men with lower serum testosterone level when treated with enzalutamide. On the contrary, progression-free survival and overall survival among men with higher serum testosterone level were significantly inferior to those among men with lower serum testosterone level when treated with docetaxel and cabazitaxel, respectively.Conclusions
The present study indicated distinct prognostic values of serum testosterone level when treated with androgen receptor axis-targeting agent and taxane chemotherapy for CRPC, suggesting that serum testosterone level may be useful predictive biomarker to navigate the appropriate therapy in patients with CRPC. 相似文献2.
3.
Yusuke Kagawa Hiromi Furuta Takehiro Uemura Naohiro Watanabe Junichi Shimizu Yoshitsugu Horio Hiroaki Kuroda Yoshitaka Inaba Takeshi Kodaira Katsuhiro Masago Shiro Fujita Akio Niimi Toyoaki Hida 《Cancer science》2020,111(12):4442
Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis of advanced NSCLC patients who received PD‐1 inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of ICIs on the patterns of progression and the efficacy of local therapy for oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated with nivolumab. Thirty‐eight patients showed oligoprogression. Male sex, a lack of driver mutations, and smoking history were significantly correlated with the risk of oligoprogression. Primary lesions were most frequently detected at oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph node (LN) oligoprogression. Four patients showed evidence of new abdominal LN oligometastases. There was no significant difference in overall survival (OS) between the local therapy group and the switch therapy group (reached vs. not reached, P = .456). We summarized clinical data on the response of oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the causes of ICI resistance and indicate that the use of local therapy as the initial treatment in this setting is feasible treatment option. 相似文献
4.
Tatsuaki Takeda Hiromasa Yamamoto Ken Suzawa Shuta Tomida Shunsaku Miyauchi Kota Araki Kentaro Nakata Akihiro Miura Kei Namba Kazuhiko Shien Junichi Soh Tadahiko Shien Yoshihisa Kitamura Toshiaki Sendo Shinichi Toyooka 《Cancer science》2020,111(3):849-856
Molecular‐targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. Neratinib is an irreversible pan‐HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2‐positive breast cancer. However, acquired resistance of various cancers to molecular‐targeted drugs is an issue of clinical concern, and emergence of resistance to neratinib is also considered inevitable. In this study, we established various types of neratinib‐resistant cell lines from HER2‐amplified breast and lung cancer cell lines using several drug exposure conditions. We analyzed the mechanisms of emergence of the resistance in these cell lines and explored effective strategies to overcome the resistance. Our results revealed that amplification of YES1, which is a member of the SRC family, was amplified in two neratinib‐resistant breast cancer cell lines and one lung cancer cell line. Knockdown of YES1 by siRNA and pharmacological inhibition of YES1 by dasatinib restored the sensitivity of the YES1‐amplified cell lines to neratinib in vitro. Combined treatment with dasatinib and neratinib inhibited tumor growth in vivo. This combination also induced downregulation of signaling molecules such as HER2, AKT and MAPK. Our current results indicate that YES1 plays an important role in the emergence of resistance to HER2‐targeted drugs, and that dasatinib enables such acquired resistance to neratinib to be overcome. 相似文献
5.
6.
Atsushi Hata Takahiro Nakajima Keisuke Matsusaka Masaki Fukuyo Junichi Morimoto Takayoshi Yamamoto Yuichi Sakairi Bahityar Rahmutulla Satoshi Ota Hironobu Wada Hidemi Suzuki Hisahiro Matsubara Ichiro Yoshino Atsushi Kaneda 《International journal of cancer. Journal international du cancer》2020,146(2):388-399
7.
8.
9.